Antipsychotic treatment, prolactin, and breast tumorigenesis

Psychiatria Danubina

Volumn 28, Issue 3, 2016, Pages 243-254

  De Hert, Marc ^a   Vancampfort, Davy ^a   Stubbs, Brendon ^b,c   Sabbe, Tine ^a   Wildiers, Hans ^a   Detraux, Johan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Breast cancer; Prolactin

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERPROLACTINEMIA; POSTMENOPAUSE; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD; BREAST TUMOR; CARCINOGENESIS; CHEMICALLY INDUCED; FEMALE; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; BREAST NEOPLASMS; CARCINOGENESIS; FEMALE; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84989854676     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Amson R, Karp J.E & Telerman A: Lessons from tumor reversion for cancer treatment. Curr. Opin Oncol 2013; 25:59-65.
2. Andres AC & Djonov V: The mammary gland vasculature revisited. J Mammary Gland Biol Neoplasia 2010; 15:319-28.
3. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al.: Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 2013; 25:368-87.
4. Aziz NA, Pijl H, Frölich M, Roelfsema F & Roos RA: Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. J Neuroendocrinol 2011; 23:519-24.
5. Azoulay L, Yin H, Renoux C & Suissa S: The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res Treat 2011; 129:541-8.
6. Barnard ME, Boeke CE & Tamimi RM: Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochem Biophys Acta 2015; 1856:73-85.
7. Ben-Jonathan N, Hugo ER, Brandebourg TD & LaPensee CR: Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17:110-6.
8. Ben-Jonathan N, Liby K, McFarland M & Zinger M: Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002; 13:245-50.
9. Berinder K, Akre O, Granath F & Hulting AL: Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011; 165:209-15.
10. Booth AK & Gutierrez-Hartmann A: Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol 2015; 846:37-59.
11. Boyle P: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012; 23:7-12.
12. Brisken C & O'Malley B: Hormone action in the mammary gland. Cold Spring Harb Perspect Biol 2010; 2:a003178.
13. Brugmans J, Verbruggen F, Dom J & Schuermans V: Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast. Lancet 1973; 2:502-3.
14. Chen WY: The many faces of prolactin in breast cancer. Adv Exp Med Biol 2015; 846:61-81.
15. Clapp C, Thebault S & Martinez de la Escalera G: Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. J Mammary Gland Biol Neoplasia 2008; 13:55-67.
16. Clevenger CV, Furth PA, Hankinson SE & Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24:1-27.
17. Connolly BS & Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670-83.
18. Dalton SO, Johansen C, Poulsen AH, Norgaard M, Sorensen HT, McLaughlin J.K, et al.: Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 2006; 95:934-9.
19. Damiano JS & Wasserman E: Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 2013; 19:1644-50.
20. Da Silva PL, do Amaral VC, Gabrielli V, Montt Guevara MM, Mannella P, Baracat EC, et al.: Prolactin Promotes Breast Cancer Cell Migration through Actin Cytoskeleton Remodeling. Front Endocrinol (Lausanne) 2015; 6:186.
21. De Hert M, Peuskens J, Sabbe T, Mitchell AJ, Stubbs B, Neven P, et al.: Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 2016; 133:5-22.
22. Dekkers OM, Romijn JA, De Boer A & Vandenbroucke JP: The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 2010; 13:195-8.
23. Deroo LA, Cummings P & Mueller BA: Smoking before the first pregnancy and the risk of breast cancer: a metaanalysis. Am J Epidemiol 2011; 174:390-402.
24. Desantis C, Ma J, Bryan l & Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64:52-62.
25. Desmarais JE & Looper KJ: Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70:1688-97.
26. Eliassen AH, Tworoger SS & Hankinson SE: Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer 2007; 120:1536-41.
27. Fahie-Wilson M & Smith TP: Determination of prolactin: the macroprolactin problem. Best Pract Res Clin Endocrinol Metab. 2013; 27:725-42.
28. Faupel-Badger JM, Ginsburg E, Fleming JM, Susser L, Doucet T & Vonderhaar BK: 16 kDa prolactin reduces angiogenesis, but not growth of human breast cancer tumors in vivo. Horm. Cancer 2010b; 1:71-9.
29. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, et al.: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 2010a; 103:1097-102.
30. Ferlay J, Forman D, Mathers CD & Bray F: Breast and cervical cancer in 187 countries between 1980 and 2010. Lancet 2012; 379:1390-1.
31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917.
32. Fernandez I, Touraine P & Goffin V: Prolactin and human tumourogenesis. J Neuroendocrinol 2010; 22:771-7.
33. Fond G, Macgregor A, Attal J, Larue A, Brittner M, Ducasse D, et al.: Antipsychotic drugs: pro-cancer or anti-cancer? A systematic review. Med Hypotheses 2012; 79:38-42.
34. Froes Brandao D, Strasser-Weippl K & Goss PE: Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses inbreast cancer patients: A review. Cancer 2016; 122:184-8.
35. Gathani T, Ali R, Balkwill A, Green J, Reeves G, Beral V, et al.: Million Women Study Collaborators: Ethnic differences in breast cancer incidence in England are due to differences in known risk factors for the disease: prospective study. Br J Cancer 2014; 110:224-9.
36. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM & Thun MJ: Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst 2013; 105:515-25.
37. Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E & Weizman A: Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 2004; 22:189-98.
38. Greendale GA, Huang MH, Ursin G, Ingles S, Stanczyk F, Crandall C, et al.: Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res Treat 2007; 105:337-46.
39. Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, et al.: Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012; 23:2997-3006.
40. Hachim IY, Hachim MY, Lopez VM, Lebrun JJ & Ali S: Prolactin receptor expression is an independent favorable prognostic marker in human breast cancer. Appl Immunohistochem Mol Morphol 2016; 24:238-45.
41. Haddad PM & Wieck A: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64:2291-314.
42. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, et al.: Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91:629-34.
43. Harvey PW: Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J Appl Toxicol 2012; 32:1-9.
44. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychoticinduced side effects. World J Biol Psychiatry 2013;14:2-44.
45. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB & Comstock GW: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994; 18:79-85.
46. Hietala M, Olsson H & Jernström H: Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk. Fam Cancer 2008; 7:221-8.
47. Hippisley-cox J, Vinogradova Y, Coupland C & Parker C: Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry 2007; 64:1368-76.
48. Holt RI & Peveler RC: Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011; 74:141-7.
49. Huang L, Zhao S, Frasor JM & Dai Y: An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 2011; 6:e22274.
50. Ingram DM, Nottage E.M & Roberts AN: Prolactin and breast cancer risk. Med J Aust 1990; 153:469-73.
51. Jacobson EM, Hugo ER, Tuttle TR, Papoian R & Ben- Jonathan N: Unexploited therapies in breast and prostate cancer blockade of the prolactin receptor. Trends Endocrinol Metab 2010; 21:691-8.
52. Kabuto M, Akiba S, Stevens RG, Neriishi K & Land CE: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol. Biomarkers Prev 2000; 9:575-9.
53. Kanhouwa S, Gowdy JM & Solomon JD: Phenothiazines and breast cancer. J Natl Med Assoc 1984; 76:785-8.
54. Ke XY, Lin Ng VW, Gao SJ, Tong YW, Hedrick JL & Yang YY: Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer tem cells. Biomaterials 2014; 35:1096-108.
55. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, et al.: Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999; 150:861-8.
56. Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hayward JL, et al.: A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer 1981; 28:673-6.
57. Lalonde FM & Myslobodsky M: Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson's disease. Breast 2003; 12:280-2.
58. LaPensee EW & Ben-Jonathan N: Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer 2010; 17:91-107.
59. Lau TK, Yip CH & Yeo W: State of the art antiemetic therapy for cancer patients. Curr Oncol Rep 2016; 18:2.
60. Lee HJ & Ormandy CJ: Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol 2012; 357:101-7.
61. Litzenburger BC & Brown PH: Advances in preventive therapy for estrogen-receptor-negative breast cancer. Curr Breast Cancer Rep 2014; 6:96-109.
62. Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K, et al.: Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis. Onco Targets Ther 2015; 8:1543-52.
63. Madhusoodanan S, Parida S & Jimenez C: Hyperprolactinemia associated with psychotropics - a review. Hum Psychopharmacol 2010; 25:281-97.
64. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, et al.: Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003; 14:599-607.
65. Matsen CB & Neumayer LA: Breast cancer: a review for the general surgeon. JAMA Surg 2013; 148:971-9.
66. Min KJ, Seo BR, Bae YC, Yoo YH & Kwon TK: Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen speciesmediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L). Cell Death Dis 2014; 5:e1063.
67. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al.: Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and metaanalysis. J Clin Oncol 2013; 31:4188-98.
68. Musey VC, Collins DC, Musey PI, Martino-Saltzman D & Preedy JR: Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316: 229-34.
69. Muthuswamy SK: Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports. Genes Dev 2012; 26: 2253-8.
70. Nagata C, Wada K, Nakamura K, Hayashi M, Takeda N & Yasuda K.: Associations of body size and reproductive factors with circulating levels of sex hormones andprolactin in premenopausal Japanese women. Cancer Causes Control 2011; 22:581-8.
71. National Cancer Institute. Available online: http://www.cancer.gov/types/breast/risk-fact-sheet#q3 (Accessed on 25 January 2016).
72. Navari RM: The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 2016; 15:343-56.
73. Navari RM: Olanzapine for the prevention and treatment of chronic nausea and chemotherapy induced nausea and vomiting. Eur J Pharmacol 2014; 722:180-6.
74. Nitze LM, Galsgaard ED, Din N, Lund VL, Rasmussen BB, Berchtold MW, et al.: Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res Treat 2013; 142: 31-44.
75. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ & Ali S: Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66:1824-32.
76. Oakes SR, Rogers RL, Naylor MJ & Ormandy CJ: Prolactin regulation of mammary gland development. J Mammary Gland Biol Neoplasia 2008; 13:13-28.
77. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE & Holly JM: Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004; 91:305-11.
78. Peuskens J, Pani L, Detraux J & De Hert M: The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28:421-53.
79. Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, et al.: Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008; 22:98-103.
80. Rahman T, Clevenger CV, Kaklamani V, Lauriello J, Campbell A, Malwitz K, et al.: Antipsychotic treatment in breast cancer patients. Am J Psychiatry 2014; 171:616-21.
81. Ranjan A, Gupta P & Srivastava SK: Penfluridol: An antipsychotic agent suppresses metastatic tumor growth in triple negative breast cancer by inhibiting integrin signaling axis. Cancer Res 2016; 76:877-90.
82. Ringnér M, Staaf J & Jönsson G: Nonfamilial breast cancer subtypes. Methods Mol Biol 2013 ; 973:279-95.
83. Ruddy KJ & Winer EP: Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 2013; 24:1434-43.
84. Rugbjerg K, Friis S, Lassen CF, Ritz B & Olsen JH: Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer 2012; 131:1904-11.
85. Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al.: Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012; 149:1284-97.
86. Sethi BK, Chanukya GV & Nagesh VS: Prolactin and cancer: Has the orphan finally found a home? Indian J Endocrinol Metab 2012; 16:195-8.
87. Stubbs B, Wang AK, Vancampfort D & Miller BJ: Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative metaanalysis. Psychoneuroendocrinology 2016; 63:144-54.
88. Tikk K, Sookthai D, Fortner RT, Johnson T, Rinaldi S, Romieu I, et al.: Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Res 2015;17: 49.
89. Tikk K, Sookthai D, Johnson T, Dossus L, Clavel- Chapelon F, Tjonneland A, et al.: Prolactin determinants in healthy women: A large cross-sectional study within the EPIC cohort. Cancer Epidemiol. Biomarkers Prev 2014b; 23:2532-42.
90. Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjonneland A, et al.: Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol 2014a; 25:1422-8.
91. Tworoger SS, Eliassen AH, Rosner B, Sluss P & Hankinson SE: Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64:6814-9.
92. Tworoger SS, Eliassen AH, Sluss P & Hankinson SE: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007; 25:1482-8.
93. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, et al.: A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013; 73:4810-9.
94. Tworoger SS & Hankinson SE: Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008; 13:41-53.
95. Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV & Hankinson SE: Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiol. Biomarkers Prev 2015; 24:73-80.
96. Tworoger SS, Sluss PM & Hankinson SE: Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 2006; 66:2476-82.
97. Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, et al.: Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and metaanalysis. World Psychiatry 2015; 14:339-47.
98. Venkitarama AR: Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 2014; 343:1470-5.
99. Wagner S & Mantel N: Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res 1978; 38:2703-8.
100. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al.: Relationship of blood prolactin levels and the risk of subsequent breast cancer. nt J Epidemiol 1992; 21:214-21.
101. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al.: The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur J Cancer Clin Oncol 1988; 24:1225-31.
102. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al.: Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59:1147-54.
103. Weigelt B & Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6:718-30.
104. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, et al.: Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 2014; 7:488-500.
105. Wiklund ED, Catts VS, Catts SV, Ng TF, Whitaker NJ, Brown AJ, et al.: Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer 2010; 126:28-40.
106. Wu L, Liu YY, Li ZX, Zhao Q, Wang X, Yu Y, et al.: Antitumor effects of penfluridol through dysregulation of cholesterol homeostasis. Asian Pac J Cancer Prev 2014; 15:489-94.
107. Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Gupta RR, et al.: The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm. Anticancer Res 1998; 18:337-48.
108. Yde CW, Clausen MP, Bennetzen MV, Lykkesfeldt AE, Mouritsen OG & Guerra B: The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anticancer Drugs 2009; 20:723-35.
109. Yeh WL, Lin HY, Wu HM & Chen DR: Combination treatment of tamoxifen with risperidone in breast cancer. PLoS One 2014; 9:e98805.
110. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al.: Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am.J Respir Crit Care Med 2012; 186:1180-8.
111. Zhelev Z, Ohba H, Bakalova R, Hadjimitova V, Ishikawa M, Shinohara Y, et al.: Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol 2004; 53:267-75.